Location History:
- Bagsvaerd, DK (1999)
- Virum, DK (2003 - 2014)
Company Filing History:
Years Active: 1999-2014
Title: **Thomas Borglum Kjeldsen: Innovator in Biotechnology**
Introduction
Thomas Borglum Kjeldsen, an accomplished inventor based in Virum, Denmark, has made significant contributions to the field of biotechnology. With a remarkable portfolio of seven patents, his work primarily revolves around the production and refinement of biologically essential molecules.
Latest Patents
Among Thomas's innovative inventions are methods for producing acylated polypeptides. This invention relates to a technique where transformed host cells express a precursor molecule of the desired polypeptide, which is subsequently acylated in an in vitro step. The patent also encompasses DNA sequences, vectors, and transformed host cells utilized in this method. Additionally, he has developed techniques for producing insulin precursors and insulin precursor analogues that boast improved fermentation yields in yeast. These novel precursors, featuring a connecting peptide and a specific amino acid composition, can be converted into human insulin or its analogs.
Career Highlights
Thomas is currently affiliated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic diseases. His dedication to advancing biotechnological methods not only showcases his inventiveness but also highlights his commitment to improving healthcare solutions.
Collaborations
Throughout his career, Thomas has worked alongside notable colleagues, including Svend Ludvigsen and Niels Christian Kaarsholm. These collaborations have likely fostered a rich environment for innovation, allowing for the exchange of ideas and development of groundbreaking technologies.
Conclusion
Thomas Borglum Kjeldsen's contributions to biotechnology exemplify the potential of innovative thinking within the field. His patents, particularly in the areas of polypeptide production and insulin precursor development, demonstrate a profound impact on the advancement of medical technologies. As he continues his work at Novo Nordisk, Thomas is set to leave a lasting legacy in health science and biotechnology.